A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB BIOSCIENCES, Inc.. Completed at 184 sites in 28 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 21 in phase 3, and was the 16th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2011.
This study's enrollment of 767 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB BIOSCIENCES, Inc., one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 6th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 72nd registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
The primary objective is to evaluate the long term safety and tolerability of BRV at individualized doses up to a maximum of 200 mg/day in epilepsy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brivaracetam with a maximum of 200 mg/day
Drug: Brivaracetam
Tablet, Flexible dosing up to 200 mg/day, twice daily. The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.
Also known as: UCB34714
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Percentage of Participants Who Withdrew Due to Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Percentage of Participants With at Least One Serious Adverse Event (SAE)
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is as infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period
The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28.
Time frame: From Baseline of the previous study until the Last Visit (up to 84 months)
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period
The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of percent change in POS frequency.
Time frame: From Baseline of the previous study until the Last Visit (up to 84 months)
Responder Rate in POS (Type I) Frequency Over the Evaluation Period
A responder is defined as a subject with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of responder rates in POS frequency.
Time frame: From Baseline of the previous study until the Last Visit (up to 84 months)
The study started to enroll patients in May 2011 and concluded in April 2019. 767 participants were included in the Enrolled Set but 1 participant from the United States of America was lost to follow-up and was excluded from the Safety Analysis Set.
| Milestone | Brivaracetam |
|---|---|
| Started | 766 |
| Completed | 368 |
| Not completed | 398 |
| Withdrew: Adverse event | 92 |
| Withdrew: Death | 5 |
| Withdrew: Lack of efficacy | 164 |
| Withdrew: Lost to follow-up | 22 |
| Withdrew: Subject choice | 89 |
| Withdrew: Protocol violation | 15 |
| Withdrew: Study closure at site | 1 |
| Withdrew: Incarcerated | 2 |
| Withdrew: Epilepsy surgery | 1 |
| Withdrew: Pregnancy planned | 2 |
| Withdrew: Left the country | 1 |
| Withdrew: Investigator decision | 2 |
| Withdrew: Patient didn't wish to continue | 1 |
| Withdrew: Pi decision | 1 |
Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
| Percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | 83.9 |
An AE is any untoward medical occurrence in a participant or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
| Percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants Who Withdrew Due to Adverse Events (AEs) | 11.9 |
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is as infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
| Percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants With at Least One Serious Adverse Event (SAE) | 18.4 |
The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28.
| Seizures per 28 days | Brivaracetam (POS Efficacy) |
|---|---|
| Baseline | 9.7 (5.5 to 23.7) |
| On Treatment | 4.2 (1.4 to 12.7) |
The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of percent change in POS frequency.
| Percent change | Brivaracetam (POS Efficacy) |
|---|---|
| Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period | 52.0 (16.8 to 81.5) |
A responder is defined as a subject with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of responder rates in POS frequency.
| Percentage of participants | Brivaracetam (POS Efficacy) |
|---|---|
| Responder Rate in POS (Type I) Frequency Over the Evaluation Period | 51.7 |
Collected over From Entry Visit (Month 0) until the Last Visit (up to 84 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam (SS) | 5/766 (0.7%) | 140/766 (18.3%) | 421/766 (55%) |
| Event | Brivaracetam (SS) |
|---|---|
| ConvulsionNervous system disorders | 15/766 |
| Status epilepticusNervous system disorders | 11/766 |
| EpilepsyNervous system disorders | 7/766 |
| Suicide attemptPsychiatric disorders | 7/766 |
| PneumoniaInfections and infestations | 5/766 |
| Suicidal ideationPsychiatric disorders | 5/766 |
| Seizure clusterNervous system disorders | 4/766 |
| CholelithiasisHepatobiliary disorders | 3/766 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 3/766 |
| HyponatraemiaMetabolism and nutrition disorders | 3/766 |
| Event | Brivaracetam (SS) |
|---|---|
| HeadacheNervous system disorders | 102/766 |
| DizzinessNervous system disorders | 100/766 |
| SomnolenceNervous system disorders | 73/766 |
| NasopharyngitisInfections and infestations | 65/766 |
| FatigueGeneral disorders | 59/766 |
| Upper respiratory tract infectionInfections and infestations | 59/766 |
| Urinary tract infectionInfections and infestations | 57/766 |
| Back painMusculoskeletal and connective tissue disorders | 46/766 |
| DepressionPsychiatric disorders | 45/766 |
| ContusionInjury, poisoning and procedural complications | 44/766 |
Baseline Characteristics refer to the Safety Set which consisted of all participants who took at least 1 dose of study medication.
| Age, Categorical(Participants) | Brivaracetam |
|---|---|
| <=18 years | 19 |
| Between 18 and 65 years | 722 |
| >=65 years | 25 |
| Age, Continuous(years) | Brivaracetam |
|---|---|
| Mean | 40.0 ± 12.9 |
| Sex: Female, Male(Participants) | Brivaracetam |
|---|---|
| Female | 396 |
| Male | 370 |
| Race/Ethnicity, Customized(Participants) | Brivaracetam |
|---|---|
| White | 561 |
| African-American | 37 |
| Asian | 85 |
| Other | 77 |
| Missing | 6 |
Showing the first 100 of 184 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2011 to primary completion in Apr 2019, 95 months.
Results were first posted in Jun 2020, 1 year 1 month after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 95 months is above that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam